A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes.
Yuan-Di C HalvorsenGeoffrey A WalfordJoseph MassaroRobert P AftringMason W FreemanPublished in: Diabetes, obesity & metabolism (2019)
Bexagliflozin at 20 mg/d was well tolerated and provided a durable, clinically meaningful improvement in glycaemic control over 96 weeks to participants in this phase 2 trial. A substantial reduction in weight and blood pressure was produced by bexagliflozin, with no increase in significant adverse event rates.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- blood pressure
- open label
- phase iii
- phase ii
- study protocol
- randomized controlled trial
- type diabetes
- systematic review
- body mass index
- hypertensive patients
- heart rate
- physical activity
- weight loss
- combination therapy
- gestational age
- body weight
- adipose tissue
- metabolic syndrome
- insulin resistance
- preterm birth
- adverse drug